Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay

Cancer Research

Volumn 57, Issue 4, 1997, Pages 678-685

  Yoshida, Minoru ^a   Rybak, Rachel J ^a   Choi, Youngnim ^a   Greenberg, Steven J ^a   Barcos, Maurice ^a   Kawata, Akira ^a   Matsuno, Fumihiko ^a   Tsai, Hilda ^a   Seon, Ben K ^a  

^a Department of Molecular Immunology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; CANCER SURVIVAL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DEGLYCOSYLATION; DISULFIDE BOND; DRUG EFFICACY; LYMPHOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA PRIMERS; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOTOXINS; LETHAL DOSE 50; LEUKEMIA, B-CELL; MALE; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; RICIN;

EID: 0031053056     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Grossbard, M. L., Press, O. W., Appelbaum, F. R., Bernstein, I. D., and Nadler, L. M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood, 80: 863-878, 1992.
2. Vitetta, E. S., Thorpe, P. E., and Uhr, J. W. Immunotoxins: magic bullets or misguided missiles? Immunol. Today, 14: 252-259, 1993.
3. Kawata, A., Yoshida, M., Okazaki, M., Yokota, S., Barcos, M., and Seon, B. K. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody. Cancer Res., 54: 2688-2694, 1994.
4. Miyoshi, I., Hiraki, S., Tsubota, T., Kubonishi, I., Matsuda, Y., Nakayama, T., Kishimoto, H., and Kimura, I. Human B-cell, T-cell, and null cell leukaemic cell lines derived from acute lymphoblastic leukemia. Nature (Lond.), 267: 843-844, 1977.
5. Minowada, J., Sagawa, K., Trowbridge, I. S., Kung, P. C., and Goldstein, G. Marker profiles of 55 human leukemia-lymphoma cell lines. In: S. A. Rosenberg and H. S. Kaplan (eds.), Advances in Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment, pp. 53-74. New York: Academic Press, 1982.
6. Okazaki, M., Luo, Y., Han, T., Yoshida, M., and Seon, B. K. Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen. Blood, 81: 84-94, 1993.
7. Brouet, J. C., Valensi, F., Daniel, M. T., Flandrin, G., Preud'homme, J. L., and Seligmann, M. Immunological classification of acute lymphoblastic leukemias: evaluation of its clinical significance in 100 patients. Br. J. Haematol., 33: 319-328, 1976.
8. Magrath, I. T., and Ziegler, J. L. Bone marrow involvement in Burkitt's lymphoma and its relationship to acute B-cell leukemia. Leukemia Res., 4: 33-59, 1979.
9. Foon, K. A., and Todd, R. F., III. Immunologic classification of leukemia and lymphoma. Blood, 65: 1-31, 1986.
10. Thorpe, P. E., Wallace, P. M., Knowles, P. P., Reif, M. G., Brown, A. N. F., Watson, G. J., Knyba, R. E., Wawrzynczak, E. J., and Blakey, D. C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res., 47: 5924-5931, 1987.
11. Greenberg, S. J., Choi, Y., Hallow, M., Du, T-L., Ward, P., Rickert, M. H., Frankel, S., Bernstein, S., and Brecher, M. Profile of immunoglublin heavy chain variable gene repertoires and highly selective detection of malignant clonotypes in acute lymphoblastic leukemia. J. Leukocyte Biol., 57: 856-864, 1995.
12. Hara, H., and Seon, B. K. Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models. Proc. Natl. Acad. Sci. USA, 84: 3390-3394, 1987.
13. Hara, H., Luo, Y., Haruta, Y., and Seon, B. K. Efficient transplantation of human non-T leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibody SN5 and SN6. Cancer Res., 48: 4673-4680, 1988.
14. Sambrook, J., Fritsch, E. F., and Maniatis, T. Isolation of high molecular weight DNA from mammalian cells. In: Molecular Cloning: A Laboratory Manual, 2nd edition, pp. 9.14-9.19. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
15. Sambrook, J., Fritsch, E. F., and Maniatis, T. Small-scale preparation of plasmid DNA. In: Molecular Cloning: A Laboratory Manual, 2nd edition, pp. 1.25-1.28. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
16. Sanger, F., Miklen, S., and Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74: 5463-5467, 1977.
17. Hamada, J., Petrino, M. G., and Kakunaga, T. Molecular structure and evolutionary origin of human cardiac muscle actin gene. Proc. Natl. Acad. Sci. USA, 79: 5901-5905, 1982.
18. Garner, I., Minty, A. J., Alonso, S., Barton, P. J., and Buckingham, M. E. A 5′ duplication of the α-cardiac actin gene in BALB/c mice is associated with abnormal levels of α-cardiac and α-skeletal actin mRNAs in adult cardiac tissue. EMBO J., 5: 2559-2567, 1986.
19. Knowles, P., and Thorpe, P. E. Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B. Anal. Biochem., 760: 440-443, 1987.
20. Takeuchi, T., Barcos, M. P., and Seon, B. K. Monoclonal antibody SNIO which shows a highly selective reactivity with human B leukemia-lymphoma and is effectively internalized into cells. Cancer Res., 57: 2985-2993, 1991.
21. Ghetie, M-A., Richardson, J., Tucker, T., Jones, D., Uhr, J. W., and Vitetta, E. S. Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res., 57: 5876-5880, 1991.
22. Yokota, S., Hara, H., Luo, Y., and Seon, B. K. Synergistic potentiation of in vivo antitumor activity of anti-human T leukemia immunotoxins by recombinant α-interferon and daunorubicin. Cancer Res., 50: 32-37, 1990.
23. Yokota, S., Qkazaki, M., Yoshida, M., and Seon, B. K. Biodistribution and in vivo antitumor efficacy of the systemically administered anti-human T leukemia immunotoxins and potentiation of their efficacy by α-interferon. Leuk. Res., 17: 69-79, 1993.
24. Amlot, P. L., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramilo, O., Thorpe, P. E., Uhr, J. W., and Vitetta, E. S. A Phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624-2633, 1993.
25. Sausville, E. A., Headlee, D., Stetler-Stevenson, M., Jaffe, E. S., Solomon, D., Figg, W. D., Herdt, J., Kopp, W. C., Rager, H., Steinberg, S. M., Ghetie, V., Schindler, J., Uhr, J., Wittes, R. E., and Vitetta, E. S. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a Phase I study. Blood, 55: 3457-3465, 1995.
26. H genes of human immunoglobulin heavy chains are encoded in 9-kilobase DNA fragments. Eur. J. Immunol., 18: 649-652, 1988.
27. Ichihara, Y., Matsuoka, H., and Kurosawa, Y. Organization of human immunoglobulin heavy chain diversity gene loci. EMBO J., 7: 4141-4150, 1988.
28. Yamada, M., Wasserman, R., Reichard, B. A., Shane, S., Caton, A. J., and Rovera, G. Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes. J. Exp. Med., 173: 395-407, 1991.
29. Choi, Y., Kotzin, B., Heron, L., Callahan, J., Marrack, P., and Kappler, J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells, Proc. Natl. Acad. Sci. USA, 86: 8941-8945, 1989.
30. Ghetie, M-A., Richardson, J., Tucker, T., Jones, D., Uhr, J. W., and Vitetta, E. S. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int. J. Cancer, 45: 481-485, 1990.
31. Schmidt-Wolf, I. G. H., Negrin, R. S., Kiem, H-P., Blume, K. G., and Weissman, I. L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med., 174: 139-149, 1991.
32. Shah, S. A., Halloran, P. M., Ferris, C. A., Levine, B. A., Bourret, L. A., Goldmacher, V. S., and Blättler, W. A. Anti-B4-bIocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res., 53: 1360-1367, 1993.
33. Kawata, A., Han, T., Dadey, B., Weier, H-U. G., Okazaki, M., Yokota, S., Fukiage, T., Xiao, H., Block, A. W., Barcos, M., Henderson, E., Yoshida, M., and Seon, B. K. Establishment and characterization of the tumors of chronic lymphocytic leukemia cell line in nude and SCID mice. Leuk. Res., 17: 883-894, 1993.
34. Thorpe, P. E., Wallace, P. M., Knowles, P. P., Reif, M. G., Brown, A. N. F., Watson, G. J., Blakey, D. C., and Newell, D. R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res., 48: 6396-6403, 1988.
35. 1. Cancer Res., 48: 2626-2631, 1988.
36. Jansen, B., Vallera, D. A., Jaszcz, W. B., Nguyen, D., and Kersey, J. H. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Cancer Res., 52: 1314-1321, 1992.
37. Schnell, R., Linnartz, C., Katouzi, A. A. Schön, G., Bohlen, H., Horn-Lohrens, O., Parwaresch, R. M., Lange, H., Diehl, V., Lemke, H., and Engert, A. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int. J. Cancer, 63: 238-244, 1995.
38. Uckun, F. M., Manivel, C., Arthur, D., Chelstrom, L. M. Finnegan, D., Tuel-Ahlgren, L., Irvin, J. D., Myers, D. E., and Gunther, R. In vivo efficacy of B43 (anti-CD19)pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood, 79: 2201-2214, 1992.
39. Denkers, E. Y., Badger, C. C., Ledbetter, J. A., and Bernstein, I. D. Influence of antibody isotype on passive serotherapy of lymphoma. J. Immunol., 135: 2183-2186, 1985.
40. Kipps, T. J., Parham, P., Punt, J., and Herzenberg, L. A. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J. Exp. Med., 161: 1-17, 1985.
41. Vitetta, E. S., and Uhr, J. W. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res., 54: 5301-5309, 1994.